Psychiatry was once big business for pharma, with drugs like Prozac making billions. Now a few breakthroughs are reviving ...

Topline data from Phase 3 EFZO-FIT study of efzofitimod in pulmonary sarcoidosis expected in the third quarter of 2025. Fourth positive DSMB review for efzofitimod in Phase 3 EFZO-FIT study reinforces ...

Topline data from Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis expected in the third quarter of 2025.Fourth positive DSMB ...

The new indication brings the drug into direct competition with Ongentys from rival Neurocrine Biosciences, which was approved for the same use last year. Adamas noted that Gocovri (amantadine ...

Biopharma companies require optimal clone yields to ensure maximum concentration and effectiveness of these therapeutic ...

Researchers have conducted the first national survey on public awareness and perceptions of food, health, and Food is ...

Meanwhile, Neurocrine Biosciences' selective muscarinic ... It came just a few days after AbbVie agreed a $10.1 billion deal to buy antibody-drug conjugate developer ImmunoGen.

Pr Amin Rostami-Hodjegan 12H30 CMU - AUDITOIRE Müller (A250) suivi d'un apéritif. Hôtes: Pr Youssef Daali & Pr Pierre FONTANA Centre facultaire d’investigation ...

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, provided a business ...

Funded by investors such as Flagship and General Catalyst, the AI startup claims its platform will help scientists speed up ...